J Lung Cancer.  2007 Dec;6(2):67-73. 10.6058/jlc.2007.6.2.67.

National Survey of Lung Cancer in Korea, 2005

• Kim YC
• Kwon YS
• Oh IJ
• Kim KS
• Kim SY
• Ryu JS
• Yum HK
• Yong SJ
• Lee KH
• Lee CG
• Lee SY
• Lee SY
• Jung MH
• Jeong ET
• In KH

• KMID: 1820247
• DOI: http://doi.org/10.6058/jlc.2007.6.2.67

Abstract

PURPOSE : Lung Cancer has been the leading cause of cancer deaths in South Korea since the year 2000, and its incidence continues to rise. Here we report the result of national survey of lung cancer conducted by Korean association for the study of lung cancer (KASLC).
MATERIALS AND METHODS
: A total of 8,788 lung cancer patients diagnosed in 2005 were registered using a web based case report form issued to hospitals equipped with more than 400 beds.
RESULTS
: The age distribution ranged from 11 to 105 years (64.7+/-0.7 years), 75.8% (6,664) of the patients were male and 28.9% of patients were never smokers. Subjective symptoms at the time of diagnosis included coughing (3,350 patients), dyspnea (2,105), chest pain (1,067), hemoptysis (805), weight loss (789), general weakness (498) and hoarseness (190), while 12% (1,015) of patients had no subjective symptoms. Of the carcinomas grouped into non-small cell lung carcinoma (NSCLC), adenocarcinoma including bronchoalveolar cell carcinoma (1.3%) was the most frequent (36.1%) histopathologic type, followed by squamous cell lung carcinoma (32.1%), large cell carcinoma (1.5%), unclassified non-small cell carcinoma (13.2%) and others (3.7%). In addition, 13.5% of all of the patients were afflicted with small cell lung carcinoma (SCLC). The stage at diagnosis was IA (7.3%), IB (10.2%), IIA (1.3%), IIB (6.1%), IIIA (12.8%), IIIB (21.6%), and IV (40.6%) in the NSCLC group. In SCLC group, 44.6% of the patients were in the limited stage, while 55.4% of the patients were in the extensive stage. The initial treatments included surgery (22.1%), radiation therapy (7.8%), chemo-radiation therapy (5.4%) and chemotherapy (38%), however, 26.6% of the patients were transferred or recorded to have supportive care only. Therefore we compared the outcomes of the Treatment Group (TG, 73.4%) and the Supportive Group (SG, 26.6%). The median survival time (MST) in months (m) was 28 (95% confidence interval 26.5~29.5 m). Multivariate analysis indicated that the independent prognostic factors for NSCLC were age, gender, ECOG PS score, stage, histopathologic type, and treatment or supportive care. In the SCLC group, age, PS score, stage, treatment or supportive care were significant prognostic factors. The TG group showed significantly superior survival when compared to the SG group, even in patients with stage IV disease and in patients that were >75 years old.
CONCLUSION
: Adenocarcinoma was found to be the most frequent histopathologic type, and active treatments were found to improve the survival of patients with lung cancer, even when they were in advanced stages or elderly

Keyword

Lung cancer; Registry; Survival; Korea

MeSH Terms

Adenocarcinoma
Age Distribution
Aged
Carcinoma, Large Cell
Chest Pain
Cough
Diagnosis
Drug Therapy
Dyspnea
Hemoptysis
Hoarseness
Humans
Incidence
Korea*
Lung Neoplasms*
Lung*
Male
Multivariate Analysis
Small Cell Lung Carcinoma
Weight Loss

Figure

• 

  Fig. 1. Web based case report form.

• 

  Fig. 2. Proportion (%) of regional population and registered patients with lung cancer. GG: Gyeonggy, GN: Gyeongnam, GB: Gyeongbuk, CC: Chungcheong, JN: Jeonnam, JB: Jeon-buk, GW: Gangwon, JJ: Jeju.

• 

  Fig. 3. Proportion (%) of smokers (current or ex-smokers) and never smokers (never-sm) by sex and histopathologic type. ADC: adenocarcinoma, non-ADC: NSCLC other than ADC, SCLC: small cell lung carcinoma.

• 

  Fig. 4. Proportion (%) of histopathologic types compared to survey data of 1997(3). SQC: squamous cell carcinoma, ADC: adenocarcinoma, LCC: large cell carcinoma, NSCLC: non-small cell lung carcinoma, SCLC: small cell lung carcinoma.

• 

  Fig. 5. Distribution (%) of stage at diagnosis compared to survey data of 1997(3).

• 

  Fig. 6. Overall survival of 8788 lung cancer patients by age group (A), by sex (B), by histopathologic types; ADC (adenocarcinoma), Non ADC (non-adenocarcinoma NSCLC), SCLC (small cell lung cancer) (C), by stage in NSCLC (D), by stage in SCLC (E) and by performance status (F). Y axis represent survival.

• 

  Fig. 7. Treatment group (TG) showed superior survival compared to supportive group (SG) not only in all patients (A), but also in patients with stage IV NSCLC (B) and patients older than 75 years (C). Y axis represent survival.

Reference

References

1. Seo JH, Jeong CS. Death rate statistics of Korea, 2003: Korea National Statistical Office;. 2004.

2. Korean Cancer Registry. Annual report of the Koean Cancer Registry. 2005.

3. Scientific Committee of Korean Academy of Tuberculosis and Respiratory Diseases. The national survey of lung cancer in Korea. Tuberculosis and Respiratory Diseases. 1999; 46:455–465.

4. Rivera MP, Stover DE. Gender and lung cancer. Clin Chest Med. 2004; 25:391–400.

5. Straus GM, Jemal A, McKenna MB, Straus JA, Cummings KM. The epidemic of smoking-related adenocarcinoma of the lung: The role of the tobacco industry and filtered and low-tar cigarettes. J of Thoracic Oncology;. 2007. Sep; Seoul, Korea; 2007. p. S305.

6. Bach PB, Kelley MJ, Tate RC, McCrory DC. Screening for lung cancer: a review of the current literature. Chest. 2003; 123(1 Suppl):72S–82S.

7. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer. 2001; 92:153–159.

8. The international early lung cancer action program investigators. International early lung cancer action program. [cited; Available from:. http://www.ielcap.org/.

9. NCI. National Lung Screening Trial. [cited; Available from:. http://www.cancer.gov/clinicaltrials/NCI-NLST#StudyIdInfo_CDR0000257938.

10. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355:1763–1771.

11. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced nonsmall cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006; 1:847–855.

12. Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory nonsmall cell lung cancer. Clin Cancer Res. 2005; 11:2244–2251.

13. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007; 110:1532–1541.